Australia markets open in 3 hours 5 minutes
  • ALL ORDS

    7,759.30
    +5.00 (+0.06%)
     
  • AUD/USD

    0.7504
    +0.0009 (+0.12%)
     
  • ASX 200

    7,443.40
    +2.40 (+0.03%)
     
  • OIL

    84.64
    +0.88 (+1.05%)
     
  • GOLD

    1,795.60
    -11.20 (-0.62%)
     
  • BTC-AUD

    82,658.23
    -1,553.04 (-1.84%)
     
  • CMC Crypto 200

    1,498.52
    -6.63 (-0.44%)
     

Global Smart Insulin Pens Market Research Report 2021: First Generation Pens & Second Generation Pens (Bluetooth Enabled, USD Connected) - ResearchAndMarkets.com

·5-min read

DUBLIN, September 16, 2021--(BUSINESS WIRE)--The "Smart Insulin Pens Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Major players in the smart insulin pens market are Companion Medical, Eli Lilly and Company, Novo Nordisk A/S, Diamesco Co. Ltd., Emperra GmbH E-Health Technologies, Digital Medics Pvt Ltd., F. Hoffmann-La Roche AG, Insulet Corporation, Jiangsu Delfu medical device Co. Ltd., and Bigfoot biomedical.

The global smart insulin pens market is expected grow from $0.082 billion in 2020 to $0.086 billion in 2021 at a compound annual growth rate (CAGR) of 4.9% The market is expected to reach $0.114 billion in 2025 at a CAGR of 7%.

The smart insulin pens market consists of sales of smart insulin pens which allows to dial the insulin dose accurately and related products. The company's manufacturing the smart insulin pens are primarily engaged in designing and manufacturing of first- and second-generation smart insulin pens which are either reusable or pre-filled for the application of delivering accurate insulin dose in Type 1 Diabetes and Type 2 Diabetes. The revenue generated by these companies is through sales of these pens to Hospitals & Clinics, Ambulatory surgical centers and Home care settings.

The smart insulin pens market covered in this report is segmented by type into first generation pens, second generation pens (Bluetooth enabled, USB connected); by end user into hospitals & clinics, ambulatory surgical centers, home care settings; by usability into prefilled, reusable and by application into type 1 diabetes, type 2 diabetes.

Accurate dose of insulin can be achieved than vial or a syringe with an insulin pen. For kids who need to take insulin during school time and visually impaired diabetic patients, an accurate dose of insulin can even be pre-set over the dosage dial which helps in accurate delivery of dose at the time of injection. Echo Plus by Novo Nordisk which is a pediatric friendly insulin pen allows even half-unit dosing with a maximum of 30 units.

HumaPen Luxura HD from Lilly allows the delivery of insulin in half-unit increments and NovoPen Junior - Insulin Pen by Novo Nordisk can deliver highly accurate doses of insulin and finely adjusts small doses even half-unit increments. The accurate adjustments and delivery of doses of insulin can avoid either over-dosing or low-dosing of the drug which is expected to increase the demand of smart insulin pens and drive the market growth.

The next generation smart insulin pens go far beyond memory storage. They help in calculating personalized doses, track glucose continuously and connects with apps of smartphones to visualize the data. In 2019, Novo Nordisk and Abbott partnered to integrate insulin dose data into the digital health tools which aims at connecting key technologies such as continuous glucose monitoring and insulin pens thus simplifying diabetes management.

The NovoPen 6 and the NovoPen Echo Plus pens will be able to connect to the Dexcom G6 CGM and the Diasend diabetes management platform (Glooko). In 2019, Companion Medical announced that the Bluetooth-enabled InPen which takes away the guesswork from dosing of insulin with an in-app bolus calculator that uses precise carbohydrate ratios and correction factors and calculates the personalized insulin doses. This enhances the ease of usage of smart insulin pens which is expected to boost the market.

Key Topics Covered:

1. Executive Summary

2. Smart Insulin Pens Market Characteristics

3. Smart Insulin Pens Market Trends And Strategies

4. Impact Of COVID-19 On Smart Insulin Pens

5. Smart Insulin Pens Market Size And Growth

5.1. Global Smart Insulin Pens Historic Market, 2015-2020, $ Billion

5.1.1. Drivers Of The Market

5.1.2. Restraints On The Market

5.2. Global Smart Insulin Pens Forecast Market, 2020-2025F, 2030F, $ Billion

5.2.1. Drivers Of The Market

5.2.2. Restraints On the Market

6. Smart Insulin Pens Market Segmentation

6.1. Global Smart Insulin Pens Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • First Generation Pens

  • Second Generation Pens (Bluetooth Enabled, USD Connected

6.2. Global Smart Insulin Pens Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Hospitals & Clinics

  • Ambulatory Surgical Centres

  • Home Care Settings

6.3. Global Smart Insulin Pens Market, Segmentation By Usability, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Prefilled

  • Reusable

6.4. Global Smart Insulin Pens Market, Segmentation 0, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7. Smart Insulin Pens Market Regional And Country Analysis

7.1. Global Smart Insulin Pens Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7.2. Global Smart Insulin Pens Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

  • Companion Medical

  • Eli Lilly and Company

  • Novo Nordisk A/S

  • Diamesco Co. Ltd.

  • Emperra GmbH E-Health Technologies

  • Digital Medics Pvt Ltd.

  • F. Hoffmann-La Roche AG

  • Insulet Corporation

  • Jiangsu Delfu medical device Co. Ltd.

  • Bigfoot biomedica

  • Injex UK

  • Smith's Medical

  • NIPRO Medical Corporation

  • Biocorp

  • BERLIN-CHEMIE

  • Diabnex

For more information about this report visit https://www.researchandmarkets.com/r/mcqlkg

View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005594/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting